PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy called P-CD19CD20-ALLO1 for people with certain B-cell cancers (like diffuse large B-cell lymphoma) that have come back or not responded to standard treatments. The therapy uses donor immune cells that are specially des…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 09:04 UTC
-
Can a simple vaccine boost immunity in CAR T-Cell patients?
Disease control OngoingThis study looks at whether giving a pneumococcal vaccine (PCV13) before and after CAR T-cell therapy can improve the body's ability to fight off pneumococcus bacteria. It involves 26 adults with certain types of lymphoma who are scheduled for CAR T-cell treatment. The main goal …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New antibody therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a new drug called epcoritamab (GEN3013) in people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is an antibody that helps the immune system attack cancer cells. The trial aims to find the best dose, check for side effects, a…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Triple-Target CAR T-Cells take on Hard-to-Treat lymphomas
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated May 11, 2026 20:38 UTC